Sign in

    Karen Johnson

    Research Analyst at Goldman Sachs

    No publicly available information can be found confirming the existence of a Karen Johnson working as an analyst at Goldman Sachs, nor any specific career or performance records related to this individual. There are no verified LinkedIn profiles, professional credentials, or coverage details tied to that name in relevant analyst roles at Goldman Sachs. If you have additional identifying information or if the query refers to another firm, please clarify for further research.

    Karen Johnson's questions to HALOZYME THERAPEUTICS (HALO) leadership

    Karen Johnson's questions to HALOZYME THERAPEUTICS (HALO) leadership • Q3 2024

    Question

    An analyst on behalf of Karen Johnson at Goldman Sachs asked for more detail on the drivers behind the increased royalty revenue guidance, such as new DARZALEX indications or conversion rates. A second question concerned the status of potential auto-injector partnership deals.

    Answer

    President and CEO Dr. Helen Torley attributed royalty growth to strong execution by partners. This includes DARZALEX share gains in frontline therapy, broadening adoption of VYVGART Hytrulo in GMG plus the new CIDP indication, and Phesgo's continued strong trajectory. Regarding auto-injectors, she confirmed that discussions are progressing through technical evaluations with potential partners.

    Ask Fintool Equity Research AI